About
Mission Bio offers the Tapestri Platform, a pioneering single-cell multi-omics solution designed to transform cancer research and precision medicine. By simultaneously capturing SNV, CNV, and protein data from the same single cell, Tapestri enables researchers to dissect clonal heterogeneity, characterize tumor architecture, and understand the mechanisms driving disease progression, therapy resistance, and relapse — insights that bulk sequencing simply cannot provide. The platform supports a broad range of capabilities including single-cell genomics, CpG methylation profiling, DNA + RNA analysis, and DNA + protein multi-omics workflows. Researchers working in hematologic malignancies (such as acute myeloid leukemia and multiple myeloma), solid tumors, genome editing quality control, and biomarker development rely on Tapestri for its end-to-end workflow — from sample preparation through bioinformatics analysis and publication-ready visualizations. Mission Bio also offers pharma assay development services for cell and gene therapy and drug development programs, as well as targeted panels that optimize sequencing budgets by focusing on key genomic regions. The Tapestri platform is especially valuable in CRISPR-based therapy development, enabling characterization of on- and off-target edits, translocations, and zygosity at single-cell resolution. It is used by pharmaceutical companies, academic cancer researchers, and clinical laboratories seeking determinative insights into tumor biology.
Key Features
- Simultaneous Multi-Omics Detection: Measures SNV, CNV, and protein data from the same individual cell in a single workflow, connecting genotype to phenotype at unprecedented resolution.
- CpG Methylation + DNA + Protein Profiling: Uncovers clonal architecture, epigenetic landscapes, and cellular differentiation all within the same cells using the Tapestri platform.
- Genome Editing Quality Control: Characterizes CRISPR edits at single-cell resolution, including on- and off-target edits, translocations, and zygosity — critical for advanced therapy development.
- Targeted Panels for Focused Sequencing: Pre-designed and custom panels focus sequencing on key genomic regions, optimizing budget and analysis time for oncology and gene therapy research.
- End-to-End Workflow with Bioinformatics: Provides an integrated pipeline from sample preparation to visualization, delivering publication-ready insights for single-cell sequencing analysis.
Use Cases
- Identifying clonal evolution and resistance mechanisms in hematologic malignancies such as AML and multiple myeloma at single-cell resolution.
- Performing CRISPR genome editing quality control to detect on- and off-target edits, translocations, and zygosity in cell and gene therapy development.
- Developing and validating biomarkers for patient stratification, therapy response prediction, and relapse monitoring in oncology drug programs.
- Profiling clonal heterogeneity in solid tumors to understand genomic diversity and guide precision medicine treatment strategies.
- Conducting multi-omics epigenetic research by simultaneously analyzing CpG methylation, DNA mutations, and protein expression from the same cells.
Pros
- Unique Multi-Omics Capability: The only platform that simultaneously detects SNV, CNV, and protein from the same cell, enabling a truly comprehensive view of cellular heterogeneity.
- Broad Application Coverage: Supports diverse research areas including hematologic malignancies, solid tumors, CRISPR genome editing, biomarker development, and pharma assay development.
- Publication-Ready Outputs: Built-in bioinformatics tools generate high-quality, publication-ready visualizations and insights, accelerating research workflows.
Cons
- Enterprise-Level Cost: As a specialized biotech platform with hardware, reagents, and services, it is likely cost-prohibitive for smaller labs or individual researchers.
- Requires Specialized Expertise: Effective use of single-cell multi-omics data requires significant bioinformatics knowledge and expertise in genomics, limiting accessibility for non-specialist teams.
- Niche Use Case: The platform is purpose-built for cancer and gene therapy research, making it unsuitable for general-purpose or non-genomics applications.
Frequently Asked Questions
What is the Tapestri Platform?
Tapestri is Mission Bio's flagship single-cell multi-omics platform. It is the first and only technology capable of simultaneously measuring SNV, CNV, and protein data from the same individual cell, enabling researchers to connect genotype and phenotype for deeper cancer biology insights.
What types of cancer research does Mission Bio support?
Mission Bio supports research in hematologic malignancies (including AML and multiple myeloma), solid tumors, precision medicine, biomarker development, and cell and gene therapy programs.
Can Mission Bio's platform be used for CRISPR genome editing analysis?
Yes. The Tapestri platform is designed for genome editing quality control, enabling characterization of on- and off-target CRISPR edits, translocations, and zygosity at single-cell resolution — essential for ensuring safety and efficacy in advanced therapies.
Does Mission Bio offer pharma assay development services?
Yes. Mission Bio provides Pharma Assay Development (PAD) services tailored for cell and gene therapy programs as well as general drug development, helping pharma teams build and validate single-cell assays.
What data types can Tapestri measure simultaneously?
Tapestri can simultaneously measure single nucleotide variation (SNV), copy number variation (CNV), protein expression, CpG methylation, and RNA — all from the same single cells, depending on the assay configuration used.
